Your session is about to expire
← Back to Search
phenelzine sulfate for Prostate Cancer
Study Summary
This trial is testing an antidepressant to treat prostate cancer that has come back. The drug works by decreasing the amount of a protein called monoamine oxidase (MAO). MAO drugs may have an anticancer effect in prostate cancer.
- Prostate Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the scope of enrollment in this scientific experiment?
"This investigation is no longer open for recruitment. First posted on September 8th 2014, its last edit was made in August 19th 2022. If you are looking to participate in other trials, there are 2239 studies enlisting prostate cancer patients and two research projects that require phenelzine sulfate participants."
Is enrollment for this research project open at the moment?
"As of the present, applications are not being accepted for this trial. It was first announced on September 8th 2014 and last edited on August 19th 2022. Other trials actively seeking participants with prostate cancer include 2239 different studies whereas phenelzine sulfate has two active recruitment programmes."
Have any other laboratory tests focused on the effects of phenelzine sulfate?
"Presently, two clinical trials are underway for phenelzine sulfate; neither of which has reached Phase 3. Most studies occur in Los Angeles yet there exist five sites trialling this medication."
Is phenelzine sulfate a reliable treatment with minimal adverse effects?
"With limited clinical data to attest for its efficacy, phenelzine sulfate scored an intermediate 2 on the safety scale. Yet, we do have past evidence that suggests it is relatively safe in a controlled medical setting."
Share this study with friends
Copy Link
Messenger